TY - JOUR
T1 - Effects of Erectile Dysfunction Drugs Use on T-Cells and Immune Markers on Men Who Have Sex with Men
AU - Park, Jee Won
AU - Arah, Onyebuchi A.
AU - Martinez-Maza, Otoniel
AU - Dobs, Adrian S.
AU - Ho, Ken S.
AU - Palella, Frank J.
AU - Seaberg, Eric C.
AU - Detels, Roger
N1 - Funding Information:
This work was supported by Baltimore CRS, U019-HL146201-01; Chicago-Northwestern CRS, U01-HL146240-01; Los Angeles CRS, U01-HL146333-01; Pittsburgh CRS, U01-HL146208-01; Data Analysis and Coordination Center, U01-HL146193-01. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health, and NIH Roadmap for Medical Research. O.A.A. was supported by the National Center for Advancing Translational Science (grant UL1-TR001881) and the National Institute of Biomedical Imaging and Bioengineering (grant R01-EB027650). O.A.A. also benefited from facilities and resources provided by the California Center for Population Research at University of California, Los Angeles, which receives core support (grant R24-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Additional support for E.C.S. was provided by the Johns Hopkins University Center for AIDS Research (P30-AI094189). The authors thank the investigators, the staff, and the participants of the MACS study for their valuable contributions.
Publisher Copyright:
© 2022 Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - Objective: Examine prospective relationships between erectile dysfunction (ED) drugs and CD4 and CD8 T-cells, and immune markers among men who have sex with men (MSM). Methods: Data from Multicenter AIDS Cohort Study, an observational prospective cohort study, with semiannual follow-ups conducted in four U.S. centers from 1998 onwards was used. Marginal structural models using g-computation were fitted to estimate the mean differences for the effects of self-reported ED drug use on CD4 and CD8 T-cell outcomes and immune biomarkers. Results: Total of 1,391 men with HIV (MWH) and 307 men without HIV (MWOH) was included. Baseline mean CD4 cell count among MWH and MWOH was 499.9 and 966.7 cells/μL, respectively. At baseline, 41.8% of MWH were virally suppressed. ED drug users reported a mean of 44.4 months of exposure to ED drugs. ED drug use was associated with increased CD4 cell outcomes among MWH but not MWOH. Mean differences in CD4 cell counts after 1 year of ED drug use was 57.6 cells/μL and increased to 117.7 after 10 years among MWH. CD8 counts were higher in ED drug users among MWH over 10 years than non-users; no consistent differences were found among MWOH. ED drug use appeared to reduce immune marker levels, such as IL-6 and increase markers, such as IL-10. We observed similar effects of ED drug use on biomarker levels among MWOH. Conclusion: Long-term use of ED drugs do not adversely affect immune function among MWH or MWOH. Future studies on the relationships between different types of ED drugs and effects on T-cell subtypes are warranted.
AB - Objective: Examine prospective relationships between erectile dysfunction (ED) drugs and CD4 and CD8 T-cells, and immune markers among men who have sex with men (MSM). Methods: Data from Multicenter AIDS Cohort Study, an observational prospective cohort study, with semiannual follow-ups conducted in four U.S. centers from 1998 onwards was used. Marginal structural models using g-computation were fitted to estimate the mean differences for the effects of self-reported ED drug use on CD4 and CD8 T-cell outcomes and immune biomarkers. Results: Total of 1,391 men with HIV (MWH) and 307 men without HIV (MWOH) was included. Baseline mean CD4 cell count among MWH and MWOH was 499.9 and 966.7 cells/μL, respectively. At baseline, 41.8% of MWH were virally suppressed. ED drug users reported a mean of 44.4 months of exposure to ED drugs. ED drug use was associated with increased CD4 cell outcomes among MWH but not MWOH. Mean differences in CD4 cell counts after 1 year of ED drug use was 57.6 cells/μL and increased to 117.7 after 10 years among MWH. CD8 counts were higher in ED drug users among MWH over 10 years than non-users; no consistent differences were found among MWOH. ED drug use appeared to reduce immune marker levels, such as IL-6 and increase markers, such as IL-10. We observed similar effects of ED drug use on biomarker levels among MWOH. Conclusion: Long-term use of ED drugs do not adversely affect immune function among MWH or MWOH. Future studies on the relationships between different types of ED drugs and effects on T-cell subtypes are warranted.
KW - Cohort studies
KW - T-lymphocytes
KW - biomarkers
KW - men who have sex with men (MSM)
KW - phosphodiesterase 5 inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85131810913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131810913&partnerID=8YFLogxK
U2 - 10.1080/19317611.2022.2084200
DO - 10.1080/19317611.2022.2084200
M3 - Article
C2 - 36387612
AN - SCOPUS:85131810913
SN - 1931-7611
VL - 34
SP - 462
EP - 473
JO - International Journal of Sexual Health
JF - International Journal of Sexual Health
IS - 3
ER -